Introduction
Development of anterior mediastinal mass after the completion of chemotherapy in children with malignant lymphoma is worrisome. Although rebound thymic hyperplasia (RTH) is not uncommon in patients after chemotherapy, 1 concern regarding lymphoma relapse may lead to further unnecessary diagnostic procedures and chemotherapy. Differentiation of RTH from lymphoma relapse is essential for clinicians. Furthermore, the relationship between RTH and the prognosis of lymphoma is not very clear. Therefore, we wish to establish possible answers based on the review of cases treated at our facility over the past 13 years.
Methods
We performed a retrospective review of 67 patients diagnosed with non-Hodgkin's lymphoma (NHL) or Hodgkin's lymphoma (HL) in a single tertiary medical center in southern Taiwan from January 1, 2001 to December 31, 2013, with follow up to their clinical course until May 30, 2015. The responses were evaluated according to the International Working Group response criteria. 2 Complete remission (CR) was defined as complete disappearance of all detectable clinical evidence of disease and diseaserelated symptoms if present before therapy. 2, 3 The definition of relapse was as follows: (1) appearance of a new lesion(s) > 1.5 cm in any axis; (2) ! 50% increase in the sum of the product of the diameters of more than one lesion from the nadir; and (3) ! 50% increase in the longest diameter of a previously identified lesion > 1 cm in short axis from the nadir. 2, 3 Thymic craniocaudal extent, maximum anteroposterior, and transverse dimensions were measured using computed tomography (CT) scans. An increase in thymus size was considered when all of the craniocaudal, anteroposterior, and transverse dimensions increased. RTH was defined as an increase in thymus size relative to the previous CT scan when patients achieved CR after chemotherapy. We also reviewed the results of gallium-67 and positron emission tomography (PET) scans. We attempted to analyze the associated risk factors for RTH. This study was approved by the institutional review board of the Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Statistical analysis
All statistical analyses were performed using SPSS statistic software, version 19.0 for Windows (IBM Company, Chicago, IL, USA). We used the chi-square or Fisher exact tests to compare the categorical variables. The chi-square test was used initially in our study. However, if there was a quadrant with expected frequencies < 5, the Fisher exact test was used instead. The ManneWhitney U test was used to compare the continuous variables. Additionally, Cox proportional hazards models were fitted with covariates selected using a backward stepwise approach. For timedependent analysis, cases that did not experience relapse were right-censored at the end of the follow-up period to control for potential differences in the duration of follow up. A two-tailed p value < 0.05 was considered statistically significant.
Results
Sixty-two of 67 patients reached CR after chemotherapy. The follow-up period ranged from 13 months to 13 years. Thirty-one patients (23 NHL, 8 HL; 22 male, 9 female) had at least two chest CT studies after CR (Figures 1 and 2 ). All but two patients had initial chest CT studies at the time of lymphoma diagnosis. Of 29 patients with initial chest CT studies, 20 patients (64.5%) had initial thoracic disease at the time of diagnosis. Twenty-one patients (67.7%) developed RTH (Table 1) . Among the patients with RTH, 14 patients (60.9%) were diagnosed with NHL and seven patients (87.5%) with HL. RTH was supported by evidence that there was a lack of uptake in other sites, and by resolution of an enlarged thymus later. Ages ranged from 3 years to 18 years, with a median age of 10 years. Thymus enlargement resolved gradually to normal size within the time period of 3 months to 5 years. Seven of 21 cases had RTH that persisted for more than 2 years. No lymphoma relapse was noted in any patients with RTH at follow up.
Some patients with chest CT-confirmed RTH also received gallium-67 and PET scans. Twenty of 21 patients with RTH received gallium scan studies. Increased gallium-67-avid radioactivities in the anterior mediastinum (1 representative is shown in Figure 3A) were noted at the time of development of RTH in nine of 20 patients (45%). Negative findings in the chest were noted in the other 11 patients. Fluorodeoxyglucose (FDG) PET/CT scans were studied in six of 21 patients with RTH and four patients (66.7%) had increased FDG-avid uptake in the anterior mediastinum at the time of development of RTH. PET revealed a well-defined concave mass in the upper anterior mediastinum with visually detectable FDG activity higher than that of the adjacent aortic arch (1 representative is shown in Figure 3B with an early maximum standardized uptake value (SUVmax) of 3.5 and a delayed SUVmax of 4.2). The early SUVmax of the other 3 patients was 3.33, 3.30, and 2.97, respectively. The delayed SUVmax was 3.13, 3.30, and 3.19, respectively. There were negative chest PET scans findings in the other 2 patients.
Twenty-eight patients who did not undergo CT scan studies at least twice were excluded from the study initially. All 28 patients underwent gallium scan studies. Increased radioactivity in the thymus only was noted at the time of development of RTH in eight of 28 patients (29%). No relapse was noted in these eight patients at follow up. PET scans were performed on three of these patients that did not have at least two CT studies, and one patient (33%) had increased FDG-avid uptake in the thymus at the time of development of RTH. This patient had no relapse at follow up. Two of 28 patients had relapse at follow up. One patient had relapse in the abdomen and bone. The PET scan showed increased FDG uptake in the abdominal paraaortic and right common iliac lymph nodes, right fourth rib, left pubis, bilateral femora, and right humerus. The other patient had relapse which was limited to the abdomen. The PET scan was not done while the gallium scan showed increased radioactivities in the right retroperitoneal region.
One patient had biopsy-documented RTH. She had an enlarged thymus after completion of chemotherapy for lymphoma. The pathology of lymphoma is shown in Figure 4A . Chest CT showed progressive enlargement of the + MODEL thymus 16 months after completion of chemotherapy. A PET scan study 2 months later still revealed increased FDGavid uptake in the thymus with moderate intensity. Due to concerns that lymphoma relapse could not be excluded, a thymectomy was eventually performed. Pathology confirmed thymic hyperplasia ( Figure 4B ). In regard to the 10/31 patients without RTH according to the chest CT studies, increased radioactivity in the thymus was noted in three of 10 patients by gallium scan. One of the 10 patients underwent a PET scan study, which showed increased FDG-avid uptake in the thymus. Interestingly, five of 10 patients without RTH had relapse in several lymph nodes at follow up (Figures 1 and 2 ). These five patients were diagnosed with NHL and all had relapse in neck lymph nodes. Other sites of relapse involved supraclavicular, mediastinal, thymus, axillary, inguinal, mesenteric, retroperitoneal lymph nodes, lung, bone marrow, and central nervous system (CNS) ( Table 2) . However, thymus size did not increase in the patients with thymus involvement at the time of relapse. No patient presented with enlargement of the thymus at the time of relapse. All patients with thymus involvement at the time of relapse also had other locations involved.
We compared the characteristics between patients with and without RTH. There were no differences in age, sex, diagnosis, stage, NHL subtypes, and chemotherapy regimens. No patient (0/21) with RTH had relapse. However, 50% (5/10) of patients without RTH had relapse. Differences in relapse were statistically significant (p Z 0.001) between patients with and without RTH ( Table 3) . If analyzed in patients with NHL only, relapse was still statistically significantly different (p Z 0.004) between patients with and without RTH. In Cox proportional hazards models, the hazard ratio of RTH to non-RTH associated with relapse is 0.008 (95% confidence interval, 0.000e16.540; p Z 0.217). If analyzed in patients with NHL only, the hazard ratio of RTH to non-RTH associated with relapse is 0.014 (95% confidence interval, 0.000e17.075; p Z 0.240).
Discussion
RTH is defined as an increase in thymus size relative to previous CT scans when patients achieved CR after chemotherapy. Physicians must be aware of this phenomenon in order to treat patients appropriately. Misinterpretations may cause prolongation of chemotherapy or unnecessary radiation therapy, biopsy, needle aspiration, or thymectomy. The development of thymic enlargement is not only present in patients with lymphoma after chemotherapy, but also in patients with other malignancy or conditions. 7 RTH has been reported in patients with osteosarcoma, nasopharyngeal carcinoma, germ cell tumor, synovial sarcoma, breast cancer, colon cancer, lung cancer, and Wilms' tumor after chemotherapy.
7e9 RTH has also been described after recovery from stress such as pneumonia, operation, after administration of steroids, and bone marrow transplantation. 7, 10, 11 Very few studies reported the incidence of RTH. The majority of previous studies present a case report or case series with diverse diagnoses. 5, 7 Kissin et al 12 reported that ALCL Z anaplastic large cell lymphoma; BM Z bone marrow; DLBCL Z diffuse large B-cell lymphoma; LBCL Z large B-cell lymphoma; NS Z nodular sclerotic; Pre-B-LBL Z precursor B-cell lymphoblastic lymphoma; Pre-T-LBL Z precursor T-cell lymphoblastic lymphoma; T-LBL Z T-cell lymphoblastic lymphoma. a The pathologic specimen was too small to categorize Hodgkin's lymphoma (HL).
thymic enlargement occurred in 14/120 adult patients (11.6%) with testicular teratomas after chemotherapy. Jeon et al 13 reported that overall incidence of RTH after radioactive iodine ablation therapy for thyroid cancer was 1.49%. In our study, because the primary sites of lymphoma did not include the chest in some patients, not all patients had received chest CT assessment during their treatment course. We excluded those patients who did not have at least two chest CT studies. By comparing chest CT studies after CR, RTH was noted in 21/31 (68%) patients who underwent at least two chest CT studies. Since CT was not performed at regular intervals for ongoing follow up, the exact incidence of RTH in patients with lymphoma after chemotherapy may be higher. The exact incidence of RTH of various tumors needs further study.
The interval from the cessation of chemotherapy to the identification of RTH ranged from 1 month to 17 months in our study. In addition, the thymic hyperplasia persisted from 3 months to 5 years and gradually faded. These are similar to previous reports. 7, 8, 12 All 21 patients with RTH in our study were asymptomatic. However, Gerhardt et al 14 reported that one patient presented with acute chest pain and dyspnea after termination of immunosuppression following renal transplant removal. CT demonstrated a blood-containing mediastinal tumor and a hemothorax. Histology confirmed RTH with secondary intrathymic bleeding.
Some reports discussed the differentiation of RTH from lymphoma relapse through chest CT morphology. Yarom et al 7 stated that features like arrowhead-shaped triangular structure and bilobulated configuration with convex borders, being located in the normal site of the thymus, and homogeneous soft tissue density favored RTH. Gallium scan is often used as a follow-up tool. However, increased radioactivity in the anterior mediastinum in a gallium-67 scan cannot differentiate RTH from lymphoma relapse. Mediastinal uptake of gallium-67 after chemotherapy in children with NHL was noted. 15 If chest CT is used as the standard for diagnosing RTH, the sensitivity and specificity Rebound thymic hyperplasia 5 of a gallium-67 scan to detect RTH are 45% (9/20) and 70% (7/10), respectively, in our study. In the past decade, the PET scan emerged as a novel lymphoma staging and followup tool. However, PET does not differentiate thymic hyperplasia from thymic neoplasia. 16 No patients with increased FDG-avid uptake in the anterior mediastinum in PET scan (4 patients with RTH, 1 patient without RTH) showed relapse in our study. Thallium-201 scan was once reported to have accumulation in the anterior mediastinum in thymic rebound. 17, 18 Inaoka et al 19 and Priola et al 20 reported that chemical-shift magnetic resonance image (MRI) was a useful tool to differentiate thymic hyperplasia from thymic tumors. Mean chemical shift ratios in the thymic hyperplasia were lower than those in the tumor group. 19 Both signal intensity index and chemical-shift ratio on chemical-shift MRI have high accuracy to distinguish thymic hyperplasia from tumors. 20 Diffusion-weighted MRI may also be helpful in cases of nonsuppressing RTH on chemical-shift MRI to facilitate differentiating benign from malignant conditions. 21 No patient had relapse of lymphoma among those patients with RTH in our study. Paradoxically, five patients had relapse of lymphoma among those patients without RTH. The hazard ratio of RTH to non-RTH associated with relapse was 0.008. Although there was no statistical significance, it was possible that the enrolled number was too small so the statistical power was too low. Heron et al 22 reported that thymic hyperplasia at the time of relapse in patients with HL was never the only finding. HL relapse with thymus enlargement was accompanied by lymph nodes disease in the mediastinum. Peylan-Ramu et al 15 found that all patients with mediastinal uptake of gallium-67 after completion of chemotherapy were disease-free with a mean follow up of 52.5 months. In our study, there were several regions of lymph node involvement in most patients with relapse. Thymic enlargement without other regions of lymph node involvement can be highly suspected as RTH and may be associated with a good feature for relapse-free status in patients with lymphoma. Thymic hyperplasia could represent a restoration of the host immune system, particularly cell-mediated immunity, an immunologic rebounding phenomenon, and it could reflect a stronger immune surveillance for children with lymphoma and favor successful control of lymphoma. 23, 24 We did not find any risk factors which were associated with RTH. The average age in patients with RTH seemed to be lower than that of patients without RTH, but this was not statistically significant. Female patients seemed to be more likely to develop RTH than male patients, but this was not statistically significant. Because the case number is too small, larger studies may be needed to further clarify these associations. Jeon et al 13 found a significantly decreased incidence of RTH from the 2 nd to the 5 th decade of age after radioactive iodine ablation therapy for thyroid cancer. In each age-related subgroup, the radioactive iodine dose was significantly higher in the RTH than the non-RTH group. Female predominance was also noted in RTH after radioactive iodine ablation therapy for thyroid cancer.
Our findings suggest that when clinicians discover patients had mediastinal widening at follow up of lymphoma, the history taking and physical examinations are important to uncover abnormal clinical manifestations. Chest CT scans may be arranged to evaluate whether any nodal diseases exist or not. If there are any new enlarged lymph nodes, diagnostic biopsy may be arranged to rule out lymphoma relapse. If there is only thymic enlargement without other abnormalities, RTH is most likely. In this situation, we propose that only a close follow up is needed. However, there were some limitations in our study. This was a retrospective study and the case number enrolled was relatively small. A larger prospective cohort study is needed to elucidate the association between RTH and relapse.
In conclusion, RTH developed in 67.7% of pediatric patients with lymphoma achieving CR after chemotherapy. If there is only thymic enlargement without other nodal diseases at follow up, RTH may be considered. Otherwise, RTH will be misclassified as thymic relapse according to the revised response criteria. 2 Therefore, isolated thymic lesion should be considered separately on the subsequent revised response guidelines. RTH seems to be associated with decreased chances for relapse but this remains undetermined. Increased uptakes in thymus in gallium-67 and FDG-PET scans are common in patients with RTH. Awareness of this phenomenon is important to prevent unnecessary surgical intervention or further chemotherapy.
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